Q1 EPS Estimate for Aclaris Therapeutics Raised by Analyst

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) – Analysts at HC Wainwright boosted their Q1 2026 EPS estimates for shares of Aclaris Therapeutics in a research note issued on Thursday, March 19th. HC Wainwright analyst R. Selvaraju now expects that the biotechnology company will post earnings per share of ($0.14) for the quarter, up from their previous estimate of ($0.15). HC Wainwright has a “Buy” rating and a $16.00 price objective on the stock. The consensus estimate for Aclaris Therapeutics’ current full-year earnings is ($0.82) per share. HC Wainwright also issued estimates for Aclaris Therapeutics’ Q2 2026 earnings at ($0.13) EPS, Q3 2026 earnings at ($0.11) EPS, Q4 2026 earnings at ($0.10) EPS, FY2026 earnings at ($0.48) EPS, Q1 2027 earnings at ($0.11) EPS, Q2 2027 earnings at ($0.12) EPS, Q3 2027 earnings at ($0.13) EPS, Q4 2027 earnings at ($0.14) EPS and FY2027 earnings at ($0.50) EPS.

ACRS has been the subject of a number of other reports. Craig Hallum started coverage on Aclaris Therapeutics in a report on Friday, January 30th. They set a “buy” rating and a $10.00 price target for the company. Weiss Ratings restated a “sell (d-)” rating on shares of Aclaris Therapeutics in a research report on Monday, December 29th. Finally, Wall Street Zen cut Aclaris Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, March 7th. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $9.80.

Aclaris Therapeutics Stock Down 1.3%

ACRS stock opened at $3.69 on Monday. The firm has a market cap of $445.01 million, a price-to-earnings ratio of -6.96 and a beta of 0.88. The company’s fifty day simple moving average is $3.41 and its 200 day simple moving average is $2.78. Aclaris Therapeutics has a 12-month low of $1.05 and a 12-month high of $4.89.

Aclaris Therapeutics (NASDAQ:ACRS) last posted its quarterly earnings data on Thursday, February 26th. The biotechnology company reported ($0.16) EPS for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.01). Aclaris Therapeutics had a negative net margin of 829.58% and a negative return on equity of 52.04%. The firm had revenue of $1.30 million during the quarter, compared to the consensus estimate of $2.07 million.

Institutional Investors Weigh In On Aclaris Therapeutics

A number of large investors have recently bought and sold shares of ACRS. ProShare Advisors LLC bought a new stake in Aclaris Therapeutics in the second quarter valued at $26,000. AXQ Capital LP bought a new position in shares of Aclaris Therapeutics during the 3rd quarter worth about $27,000. Police & Firemen s Retirement System of New Jersey bought a new position in shares of Aclaris Therapeutics during the 2nd quarter worth about $28,000. XTX Topco Ltd acquired a new stake in shares of Aclaris Therapeutics in the 2nd quarter valued at about $34,000. Finally, R Squared Ltd acquired a new stake in shares of Aclaris Therapeutics in the 4th quarter valued at about $37,000. 98.34% of the stock is currently owned by institutional investors and hedge funds.

Key Headlines Impacting Aclaris Therapeutics

Here are the key news stories impacting Aclaris Therapeutics this week:

• Positive Sentiment: HC Wainwright reiterated a “Buy” rating with a $16 price target and raised FY2026 and FY2027 EPS forecasts (FY2026 to ($0.48) from ($0.52); FY2027 to ($0.50) from ($0.55)), implying meaningful upside vs. the current share price and signaling the analyst sees improving financial trends. Article Title
• Positive Sentiment: HC Wainwright also raised several near-term quarterly estimates (examples: Q4 2026 to ($0.10) from ($0.11); Q3 2026 to ($0.11) from ($0.12); Q2 2026 to ($0.13) from ($0.14); Q1 2026 to ($0.14) from ($0.15)), suggesting incremental improvement in expected cash burn and operating performance. Article Title
• Neutral Sentiment: Despite upward revisions, the analyst model still projects continued losses across 2026–27 (quarterly losses in the ~$0.10–$0.14 range and FY losses of ($0.48)–($0.50)), so near-term profitability remains distant and dependent on execution or product/catalyst progress. Article Title
• Negative Sentiment: Recent reported results (Feb. 26) missed consensus on both EPS and revenue and showed very large negative margins and ROE, which likely underpins today’s selling pressure despite the bullish price target — investors remain cautious until the company shows consistent revenue growth or margin improvement. Article Title

Aclaris Therapeutics Company Profile

Aclaris Therapeutics, Inc (NASDAQ:ACRS) is a clinical‐stage biopharmaceutical company focused on discovering, developing and commercializing novel small‐molecule therapies for dermatologic diseases and related rare disorders. The company’s pipeline includes several product candidates designed to address chronic inflammatory skin conditions and non‐melanoma skin lesions. Lead programs include ATI‐50002, a topical agent in late‐stage development for molluscum contagiosum removal; ATI‐50003 for common wart resolution; ATI‐1501, an oral JAK1/2 inhibitor targeting pruritic disorders; and ATI‐450, an oral MK2 inhibitor for inflammatory indications.

Founded in 2016 and headquartered in Malvern, Pennsylvania, Aclaris leverages proprietary chemistry platforms and translational research capabilities to advance multiple clinical and preclinical candidates.